- Home
- AB vs CRNX Comparison
AB vs CRNX Comparison
Compare AB & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AB
- CRNX
- Stock Information
- Founded
- AB 1987
- CRNX 2008
- Country
- AB United States
- CRNX United States
- Employees
- AB N/A
- CRNX N/A
- Industry
- AB Investment Managers
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- AB Finance
- CRNX Health Care
- Exchange
- AB Nasdaq
- CRNX Nasdaq
- Market Cap
- AB 4.5B
- CRNX 4.1B
- IPO Year
- AB 1988
- CRNX 2018
- Fundamental
- Price
- AB $39.65
- CRNX $41.44
- Analyst Decision
- AB Hold
- CRNX Buy
- Analyst Count
- AB 5
- CRNX 12
- Target Price
- AB $41.00
- CRNX $71.27
- AVG Volume (30 Days)
- AB 165.7K
- CRNX 1.5M
- Earning Date
- AB 10-23-2025
- CRNX 11-06-2025
- Dividend Yield
- AB 8.21%
- CRNX N/A
- EPS Growth
- AB N/A
- CRNX N/A
- EPS
- AB 3.03
- CRNX N/A
- Revenue
- AB N/A
- CRNX $1,535,000.00
- Revenue This Year
- AB N/A
- CRNX $405.68
- Revenue Next Year
- AB $8.36
- CRNX $1,034.87
- P/E Ratio
- AB $13.09
- CRNX N/A
- Revenue Growth
- AB N/A
- CRNX 47.74
- 52 Week Low
- AB $32.28
- CRNX $24.10
- 52 Week High
- AB $43.30
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- AB 52.96
- CRNX 48.52
- Support Level
- AB $39.01
- CRNX $38.82
- Resistance Level
- AB $39.87
- CRNX $43.48
- Average True Range (ATR)
- AB 0.59
- CRNX 1.94
- MACD
- AB -0.04
- CRNX -0.30
- Stochastic Oscillator
- AB 38.42
- CRNX 42.94
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.